Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01416857 · ClinicalTrials.gov registry record · NA
Emergency Department (ED) Disability Diagnostic Tool
A NA study, sponsored by Yale University.
- Completed
- Registry status
- NA
- Development phase
- 635
- Enrollment target
NCT01416857: Completed NA study, sponsored by Yale University.
NCT01416857 is a NA study that has completed, run by Yale University. The registered enrollment target is 635 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01416857, a NA study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- NA
- Development phase
- 635 participants
- Enrollment target
Study Summary
Aim 1: To develop and validate an Emergency Department(ED) Rasch Disability Diagnostic Tool (RDDT). Hypothesis: * Rasch modeling will provide an instrument with better measurement properties, including increased reliability and validity compared to currently available ED measure of disability (MOD). Aim 2: To conduct a randomized controlled trial to evaluate the utility of the ED-RDDT to reduce rehospitalizations in Medicare recipients visiting an urban Emergency Department for non-traumatic illness Hypotheses: * Compared to the standard screening tool, the ED RDDT will reduce reutilization of the hospital (ED visits, hospital admissions, or death) within 60 days of discharge. * The ED RDDT will reduce costs to Medicare, hospitals and patients.
Interventions
- OTHER RDDT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 635 participants |
| Start Date | 2011-08 |
| Est. Completion | 2014-03 |
| Phase | NA |
What the finished NCT01416857 record still lists
NCT01416857 is an interventional study that assigns participants to a tested intervention. The registered 635 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 1 intervention - of which RDDT is the first listed.
NCT01416857 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01416857 about?
NCT01416857 is a clinical study titled "Emergency Department (ED) Disability Diagnostic Tool". Aim 1: To develop and validate an Emergency Department(ED) Rasch Disability Diagnostic Tool (RDDT). Hypothesis: * Rasch modeling will provide an instrument with better measurement properties, including increased reliability and validity compared to currently available ED measure of disability (MOD...
What is the current status of trial NCT01416857?
This trial is currently completed. It is a NA study. The enrollment target is 635 participants. The study started on 2011-08. Estimated completion is 2014-03.
What interventions are being tested in trial NCT01416857?
The interventions under investigation include: RDDT (OTHER).
Who is sponsoring clinical trial NCT01416857?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01416857's enrollment target sits among peer trials
635 158th of 2000 higher than 1,843 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03478826 · 635 participants
Creation of a Biospecimen Repository From Patients With Interstitial Lung Diseases (ILD)
- NCT03821129 · 636 participants · NA
GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study
- NCT00573027 · 634 participants · NA
Heart Disease of the Small Arteries in Women and Men
- NCT04108156 · 634 participants · Phase 3
A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia